This is an interview with Dr. Paul Wotton, who joined Cynata Therapeutics Board of Directors in June, 2016. Dr. Wotton was previously President and CEO of Ocata Therapeutics, Inc. (NASDAQ: OCAT) joining the company in July 2014 and managing it through an all-cash take-over by Astellas Pharma valued at $379 million. [Read more…]
NurOwn® – BrainStorm Signs Dana-Farber as Second Manufacturing Site in U.S.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) has contracted with the Cell Manipulation Core Facility at Dana-Farber Cancer Institute to manufacture NurOwn® for the company’s ongoing multi-dose Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). Dana-Farber will be the second U.S. manufacturing site to supply NurOwn for BrainStorm Cell Therapeutics’ ongoing trial. [Read more…]
Eppendorf introduces first ready-to-use, synthetic cell cultureware for iPSC and MSC stem cells
Hamburg, June 2018 – Since the groundbreaking discovery of human induced pluripotent stem cells (hiPSCs) by Shinya Yamanaka in 2006, the use of pluripotent stem cells (PSCs) has experienced a boom. Due to their extensive in vitro self-renewal properties and their ability to differentiate into many different cell types, PSCs, and especially hiPSCs, offer exciting promises in a wide range of cell applications including regenerative medicine. [Read more…]
Things To Know About An Autologous Stem Cell Transplant
“Autologous stem cell transplant” can be a mouthful to say. Many people don’t know what it means – let alone what a reliable option it is for defeating blood and bone-borne cancers. It has also demonstrated improvements in progression-free survival (PFS). Many of those who undergo the procedure can drive their cancer into remission or permanently defeat it. [Read more…]
Cynata Reports Positive 28-day Data from Cohort B of Phase 1 Trial of CYP-001 in GvHD
MELBOURNE, Australia, June 21, 2018 — Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce positive safety and efficacy data from a day 28 analysis of patients in Cohort B of its Phase 1 clinical trial of CYP-001, the Company’s lead Cymerus™ mesenchymal stem cell (MSC) product candidate, in steroid-resistant acute graft-versus-host disease (GvHD). [Read more…]
- « Previous Page
- 1
- …
- 113
- 114
- 115
- 116
- 117
- …
- 202
- Next Page »